**BACKGROUND**

- Systemic mycoses are fungal infections mainly transmitted through inhalation of conidia or spores via the broncho-pulmonary tract. Systemic mycoses can remain in the lung as an acute or chronic infection, or disseminate throughout the rest of the body via the alveolar systemic circulation (Whitl 2016).
- SUBA-itraconazole capsules (SUBA-itra) is a triazole antifungal agent approved by the United States (US) Food and Drug Administration (FDA) for the treatment of systemic fungal infections caused by Histoplasmosis (including chronic cavitary pulmonary disease and disseminated, non-merging histoplasmosis), Blastomycosis (pulmonary and extrapulmonary), and Aspergillosis (US FDA 2018).
- SUBA-technology is a novel technology for enhancing the bioavailability of poorly soluble drugs.
- The technology utilizes a solid dispersion of the drug in a polymer matrix to improve absorption in the gastrointestinal tract resulting in nearly double the bioavailability compared to that of conventional oral itraconazole capsules.

**OBJECTIVES**

The objective of this analysis was to estimate the incremental budget impact (BI) of adopting SUBA-itra, a new oral formulation of itraconazole, in adult systemic mycoses (SM) patients.

**RESULTS**

Table 1: Market share distribution

<table>
<thead>
<tr>
<th>PARAMETER</th>
<th>VALUE</th>
<th>SOURCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>7,000,000</td>
<td>Assumption</td>
</tr>
<tr>
<td>Year</td>
<td>2019</td>
<td>Assumption</td>
</tr>
<tr>
<td>Market Share</td>
<td>SUBA-itra</td>
<td>10%</td>
</tr>
<tr>
<td></td>
<td>Itraconazole</td>
<td>90%</td>
</tr>
</tbody>
</table>

Table 2: Model inputs and sources (base case)

<table>
<thead>
<tr>
<th>PARAMETER</th>
<th>VALUE</th>
<th>SOURCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population size</td>
<td>1,000,000</td>
<td>Assumption</td>
</tr>
<tr>
<td>Outcome year</td>
<td>2019</td>
<td>Assumption</td>
</tr>
<tr>
<td>Market share percentage</td>
<td>SUBA-itra: 10%</td>
<td>Assumption</td>
</tr>
<tr>
<td></td>
<td>Itraconazole: 90%</td>
<td>Assumption</td>
</tr>
</tbody>
</table>

Table 3: Cost summary

- **Drug costs**
  - **And itraconazole**
    - **Cost per patient**
      - **SUBA-itra**
        - **Itraconazole**
          - **Posaconazole**

**CONCLUSIONS**

- Based on the present model, the introduction of SUBA-itra had a budget impact of $55,376 over three years for a hypothetical health plan of 1 million US members.
- The model demonstrated moderate sensitivity to variation in the proportion of generic itraconazole and the retreatment duration.

**REFERENCES**

5. Ontario Case Communication. 2018.10.01.

**ISPOR 2019 (New Orleans)**

Study sponsored by Mayne Pharma Raleigh, NC. Contact: Anna Pérez-Ruiz, +1 449-585-3212.